The bidding war goes on to acquire Obagi Medical Products (NASDAQ:OMPI) and its dermatological product line, with the acquisitive Valeant Pharmaceuticals (NYSE:VRX) as the current top bidder at $24 per share. The ongoing bidding war has Obagi up another 10% today. Are we close to seeing a deal? In this video, Fool health-care analyst David Williamson tells investors how to play this buyout bidding race, both for current shareholders, and for those currently sitting on the sidelines.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.